Saturated acyl guanidine for inhibition of F1F0-ATPase
US9580391B2 · kind B2 · utility
4Cited by
9References
30Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 2013 |
| Grant date | Feb 28, 2017 |
| Priority date | — |
| Expiry date | Jun 7, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D231/38
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.